The experiment involved thirty male rats divided into six groups. One group received saline as a control, another received monosodium iodoacetate (MIA) to induce OA, and the remaining four groups received MIA alongside various treatments: chitosan NPs, curcumin-loaded chitosan at two different doses (150 mg/kg and 300 mg/kg), or ibuprofen, a common pain medication. The researchers monitored changes in the knee joints by measuring their diameter and examining X-ray images throughout the experiment. The results revealed that curcumin nanoparticles, particularly at the higher dose (300 mg/kg), were significantly more effective than chitosan or the lower curcumin dose (150 mg/kg) in reducing joint swelling and preventing cartilage degeneration. Interestingly, this higher dose of curcumin nanoparticles demonstrated effectiveness comparable to ibuprofen. These findings suggest that curcumin nanoparticles have the potential to be a valuable therapeutic agent for OA. Their anti-inflammatory properties may offer relief from pain and swelling in the joints, while the nanoparticle delivery system may improve curcumin's bioavailability and effectiveness compared to traditional curcumin. The study paves the way for curcumin nanoparticles as a potential alternative to NSAIDs for OA patients who experience side effects or intolerance to these medications.